Wells Fargo & Co Reiterates “$245.00” Price Target for Allergan (AGN)
Allergan (NYSE:AGN) has been assigned a $245.00 target price by Wells Fargo & Co in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Wells Fargo & Co’s price target suggests a potential upside of 42.67% from the stock’s previous close.
Several other research firms have also recently commented on AGN. ValuEngine cut Allergan from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Royal Bank of Canada set a $218.00 target price on Allergan and gave the stock a “buy” rating in a research report on Thursday. Mizuho restated a “buy” rating and set a $267.00 target price on shares of Allergan in a research report on Monday, September 25th. Barclays restated an “equal weight” rating on shares of Allergan in a research report on Monday, October 2nd. Finally, UBS Group restated a “buy” rating and set a $275.00 target price on shares of Allergan in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $230.99.
Allergan (NYSE:AGN) opened at $171.73 on Friday. The firm has a market capitalization of $57,060.00, a price-to-earnings ratio of -7.60, a PEG ratio of 1.16 and a beta of 1.11. Allergan has a 52-week low of $160.07 and a 52-week high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.32 earnings per share. analysts anticipate that Allergan will post 16.27 EPS for the current year.
Allergan declared that its board has initiated a stock repurchase plan on Monday, September 25th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
In related news, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were bought at an average cost of $163.30 per share, with a total value of $1,633,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider William Meury sold 11,807 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Insiders purchased a total of 17,630 shares of company stock worth $2,890,057 over the last ninety days. 0.36% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Pathstone Family Office LLC grew its position in shares of Allergan by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after purchasing an additional 366 shares in the last quarter. Howard Hughes Medical Institute purchased a new position in Allergan in the second quarter worth about $103,000. Massey Quick & Co. LLC lifted its stake in Allergan by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares during the last quarter. Cable Hill Partners LLC lifted its stake in Allergan by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the last quarter. Finally, Pacific Center for Financial Services lifted its stake in Allergan by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the last quarter. Institutional investors and hedge funds own 81.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/05/wells-fargo-co-reiterates-245-00-price-target-for-allergan-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.